AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34517775
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between number of medications and number of PIMs
Trial: 34517775
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between number of medications and anticholinergic score
Trial: 34268888
Drug: Large volume
RxNorm normalized name: NEBULIZER,LARGE VOLUME #1770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large volume subcutaneous injection (1, 8, and 20 cP viscosities, up to 10ml in abdomen and 5ml in thigh)
Trial: 34268888
Drug: Large volume
RxNorm normalized name: NEBULIZER,LARGE VOLUME #1770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large volume subcutaneous injection
Trial: 34790138
Drug: Betahistine (72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (72 mg/d)
Trial: 35835135
Drug: Doxorubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin plus trabectedin (60 mg/m2 doxorubicin and 1.1 mg/m2 trabectedin)
Trial: 35835135
Drug: Doxorubicin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin alone (75 mg/m2)
Trial: 33749741
Drug: Intravenous 8‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 8‐mg dose of dexamethasone
Trial: 33090380
Drug: P‐Ser treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P‐Ser treatment for 12 months
Trial: 35970815
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (n=203)
Trial: 35970815
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic treatment (n=360)
Trial: 35970815
Drug: Rifaximin treatment
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin treatment (specific numbers not provided)
Trial: 35970815
Drug: Long-term antibiotic
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antibiotic prophylaxis at discharge (specific numbers not provided)
Trial: 32319076
Drug: Levodopa inhalation
RxNorm normalized name: levodopa Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa inhalation powder 84 mg
Trial: 32247315
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride (BH) spray
Trial: 35559243
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of ziprasidone (60–80 mg/d) in combination with sertraline
Trial: 35559243
Drug: Usual dose
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dose of ziprasidone (120–160 mg/d) monotherapy
Trial: 35322843
Drug: Cranberry (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry (9 g powder solubilized in water equivalent to 100 g of fresh cranberries, 525 mg total (poly)phenols)
Trial: 35322843
Drug: Control (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (9 g powder, no (poly)phenols)
Trial: 34567223
Drug: Peppermint essential
RxNorm normalized name: Nature's Truth Peppermint Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint essential oil (3 drops inhaled for 7 nights)
Trial: 34567223
Drug: Lavender essential
RxNorm normalized name: Nature's Truth Lavender Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender essential oil (3 drops inhaled for 7 nights)
Trial: 34567223
Drug: Control (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (3 drops of aromatic placebo inhaled for 7 nights)
Trial: 34644472
Drug: Cell-culture-derived quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell-culture-derived quadrivalent inactivated influenza vaccine (IIV4c)
Trial: 34644472
Drug: Meningococcal ACWY
RxNorm normalized name: meningococcal ACWY, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal ACWY vaccine (control)
Trial: 34131001
Drug: Crossover veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover veliparib monotherapy (300-400 mg twice daily continuous)
Trial: 34131001
Drug: Crossover veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover veliparib monotherapy
Trial: 32157678
Drug: Individually customized
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually customized tapering plan at discharge combined with telephone counselling one week after discharge
Trial: 32157678
Drug: No tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No tapering plan or telephone counselling
Trial: 38367750
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg vaginal misoprostol
Trial: 38367750
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg vaginal misoprostol
Trial: 35908869
Drug: PCV13 (13-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 (13-valent pneumococcal vaccine)
Trial: 32702912
Drug: Low-intensity pelvic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity pelvic floor muscle training (PFMT) twice a week for 15 minutes per day for 12 weeks
Trial: 33350994
Drug: Caffeinated energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated energy dietary supplement (55 mg of caffeine)
Trial: 35570329
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone (8 mg)
Trial: 34661562
Drug: Smart pill
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smart pill bottle reminder intervention for 4 weeks
Trial: 33595885
Drug: Excimer light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excimer light and topical calcipotriol
Trial: 32901654
Drug: Silica gel
RxNorm normalized name: Silica gel
DrugBank: Silicon dioxide (DB11132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silica gel desiccator (27.19 °C, 26.19% RH) for drying
Trial: 36282407
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS); 18 sessions (twice a week for nine weeks)
Trial: 35482651
Drug: Behaviorally based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviorally based weight-loss treatments (BBWLTs)
Trial: 32558218
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents after OA
Trial: 33143547
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kgBW)
Trial: 32046537
Drug: Whole-body hot
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body hot pack thermal therapy (HPTT)
Trial: 32046537
Drug: Waon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waon therapy (WT)
Trial: 32126990
Drug: Topical regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical regimen
Trial: 39046695
Drug: Long-acting muscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting muscarinic antagonist (LAMA)
Trial: 34537184
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial appendage occlusion (LAAO) using Amplatzer Amulet or Watchman FLX with lifelong aspirin 75 mg daily
Trial: 32577745
Drug: Levothyroxine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (starting with 50 μg, adjusted for weight and coronary heart disease)
Trial: 38627668
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 0.15 mg/kg
Trial: 36071444
Drug: Step-up arm:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-up arm: Intra-articular corticosteroid injection (IACI) in all affected joints for less severe oligoarthritis; IACI and methotrexate for polyarthritis or severe oligoarthritis.
Trial: 36071444
Drug: Step-down arm:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down arm: 6-month early combined treatment (methotrexate plus IACI for less severe oligoarthritis; methotrexate plus etanercept for severe oligoarthritis and polyarthritis).
Trial: 34309839
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) at 70 L min−1
Trial: 32127550
Drug: Ecologic Femi+
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ecologic Femi+ vaginal capsule
Trial: 32127550
Drug: Gynophilus LP
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynophilus LP vaginal tablet
Trial: 33430957
Drug: Computer-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based cognitive training intervention using Attentive Rehabilitation of Attention and Memory (ARAM) software, 45 minutes per session, twice a week for 10 sessions.
Trial: 35346115
Drug: Psychotherapy (cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy (cognitive behavioural therapy)
Trial: 33371483
Drug: 2S-Hesperidin 500
RxNorm normalized name: hesperidin complex 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2S-Hesperidin 500 mg/day
Trial: 33371483
Drug: Placebo (microcellulose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (microcellulose) 500 mg/day
Trial: 32971314
Drug: Acute-phase cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute-phase cognitive therapy (CT)
Trial: 36195993
Drug: Nitrate treatment
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate treatment
Trial: 36264097
Drug: Actovegin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin (1200 mg daily, intravenously for two weeks, followed by oral administration for 10 weeks)
Trial: 33038289
Drug: Deutetrabenazine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine 15 mg (fed state)
Trial: 33038289
Drug: Deutetrabenazine 7.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine 7.5, 15, and 22.5 mg (repeated dosing)
Trial: 33038289
Drug: Deutetrabenazine 6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine 6, 12, 18, and 24 mg (with standard meal)
Trial: 33038289
Drug: Deutetrabenazine 18
RxNorm normalized name: deutetrabenazine 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine 18 mg (with high-fat meal)
Trial: 33038289
Drug: Deutetrabenazine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine (any dose)
Trial: 33038289
Drug: Tetrabenazine 25
RxNorm normalized name: tetrabenazine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrabenazine 25 mg (fasted state)
Trial: 33887492
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue sealant (2 ml per 100 cm2 surface area)
Trial: 35523943
Drug: Tolcapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (200 mg t.i.d.)
Trial: 33148308
Drug: Rescue intervention
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue intervention strategy (RIS) with budesonide/formoterol plus original treatment until AQI < 200
Trial: 33148308
Drug: Original treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original treatment (no inhaled medicine, SABA on demand, or budesonide/formoterol 160 μg/4.5 μg/dose, 1–2 dose/time, b.i.d.)
Trial: 36098814
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg) administered 1 hour before surgery
Trial: 35045567
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate (ALN) 70 mg weekly for 52 weeks
Trial: 34029455
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (250 mg every 4 weeks)
Trial: 32271183
Drug: FDC IBU/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC IBU/APAP 250/500 mg
Trial: 34304913
Drug: IBU 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBU 250 mg
Trial: 35965962
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion combined with crystalloid coload
Trial: 35965962
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion combined with colloid coload
Trial: 33482135
Drug: Ningmitai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ningmitai capsule (NMT)
Trial: 32157418
Drug: Ruxolitinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib treatment
Trial: 33713057
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen at 10mg/kg/dose 8 hourly
Trial: 33713057
Drug: Intravenous diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diclofenac sodium at 1mg/kg/dose 8 hourly
Trial: 32683359
Drug: Standard antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotics (penicillin or ampicillin)
Trial: 33915251
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2)
Trial: 35855841
Drug: TWG tablets
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TWG tablets + acitretin capsules (Group A)
Trial: 35855841
Drug: Compound glycyrrhizin
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound glycyrrhizin capsules + acitretin capsules (Group B)
Trial: 35855841
Drug: Acitretin capsules
RxNorm normalized name: Acitretin Capsules
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin capsules (Group C)
Trial: 36470077
Drug: SCTV01C 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTV01C 20 μg
Trial: 36470077
Drug: SCTV01C 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTV01C 40 μg
Trial: 32199723
Drug: Top concern
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top concern group (control + video addressing the top HPV vaccine concern)
Trial: 35500460
Drug: Durvalumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab with concurrent chemoradiotherapy (CCRT) including etoposide and cisplatin, 4 cycles every 3 weeks, followed by durvalumab consolidation therapy every 4 weeks for up to 2 years.
Trial: 33592841
Drug: T-MSAT +
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-MSAT + integrative Korean medicine therapy (IKMT)
Trial: 32343940
Drug: Uvulopalatopharyngoplasty (UPPP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uvulopalatopharyngoplasty (UPPP) with hyoid suspension (HS)
Trial: 32343940
Drug: Barbed reposition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barbed reposition pharyngoplasty (BRP) with hyoid suspension (HS)
Trial: 33347474
Drug: Rotavirus vaccine
RxNorm normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotavirus vaccine (RV) and pneumococcal conjugate vaccine (PCV)
Trial: 34982486
Drug: 1.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g/day of EPA/DHA
Trial: 33581283
Drug: 20 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Hz rTMS treatment at the dorsolateral prefrontal cortex (DLPFC) for 30 sessions over six weeks (five days per week) with a three-month follow-up.
Trial: 33581283
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment group for 30 sessions over six weeks (five days per week) with a three-month follow-up.
Trial: 34323584
Drug: Maximum likelihood
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum likelihood (ML)
Trial: 35199592
Drug: Olive cream
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive cream
Trial: 35301133
Drug: Aspirin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (two common dosages)
Trial: 35373017
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg Dulaglutide (DU) weekly
Trial: 35373017
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine (IG) daily
Trial: 34682669
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy Group (PTG)
Trial: 32901323
Drug: Conventional Treatment
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Treatment (Group C)
Trial: 38525605
Drug: MRA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRA treatment
Trial: 34212476
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral (DAA) therapy
Trial: 35357350
Drug: Increased anti-infective
RxNorm normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased anti-infective treatment
Trial: 37454789
Drug: 38% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% silver diamine fluoride (SDF) solution
Trial: 36352742
Drug: All experimental
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All experimental treatments (including RSM and FRSM)
Trial: 35157830
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg orally twice daily)
Trial: 35157830
Drug: Control (enzalutamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (enzalutamide 160 mg orally once daily or abiraterone 1000 mg orally once daily plus prednisone 5 mg orally twice daily)
Trial: 36360996
Drug: TaU +
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TaU + MIND (treatment as usual plus mindfulness-based therapy)
Trial: 37452281
Drug: TaU (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TaU (treatment as usual)
Trial: 34541872
Drug: RG‐TFV rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG‐TFV rectal gel daily
Trial: 34541872
Drug: RG‐TFV rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG‐TFV rectal gel before and after receptive anal intercourse (RAI)
Trial: 34541872
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three PrEP regimens (RG‐TFV daily, RG‐TFV before and after RAI, and daily oral FTC/TDF)
Trial: 34556559
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving four sequential biphasic shocks of 150 J, 200 J, 360 J and 360 J with chest pressure on the last shock.
Trial: 33395734
Drug: Treatment Group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Group 2 (n=18) received a booklet, a tailored care plan, and four coaching sessions
Trial: 33395734
Drug: Treatment Group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Group 1 (n=7) received an educational booklet
Trial: 35050957
Drug: Inhaled nitrous
RxNorm normalized name: nitrous oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrous oxide/oxygen (N2O/O2) 50%-50% equimolar mixture (EMONO)
Trial: 32964918
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 21 g (300 mg/kg) for 20 hours
Trial: 32745306
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy for 5 days
Trial: 32745306
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy for 3 days
Trial: 32298202
Drug: CART-19 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CART-19 (high dose 5 × 10^8)
Trial: 32298202
Drug: CART-19 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CART-19 (low dose 5 × 10^7)
Trial: 35144958
Drug: IMPACT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IMPACT intervention (mHealth application, symptom watch, tailored health intervention) for 8 weeks with weekly activities including symptom monitoring, goal setting, and progress monitoring.
Trial: 33433041
Drug: NB-UVB phototherapy
RxNorm normalized name: Nb
DrugBank: Niobium (DB13031)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB-UVB phototherapy plus 480 mg oral Polypodium leucotomos (PL) twice daily
Trial: 34128884
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency (PRF) at 42°C for 120 seconds plus oral alpha lipoic acid (ALA) 600 mg three times per day for 3 weeks then 600 mg once daily for 2 weeks